News

April 12, 2017

New Tissue Imaging and Collecting Technique Can Identify Mesothelioma Subtypes

News

German researchers have come up with a new tissue-sample imaging and collecting technique for identifying diffuse malignant mesothelioma (DMM) subtypes. The method that the team at Ruhr-University Bochum developed is based on advanced ... Read more

April 11, 2017April 11, 2017

Blood Levels May Help Diagnose, Monitor Asbestos-Related Diseases, Chinese Study Finds

News

High levels of a naturally occurring protein, high-mobility group box 1 (HMGB1), are present in the blood of people with asbestos exposure and even higher in two asbestos-related diseases — ... Read more

April 10, 2017April 10, 2017

Verastem Presents Its Mesotheliomia Therapy Defactinib at New York Conference

News

Verastem‘s mesothelioma therapy Defactinib (VS-6063), which a 2016 report said shrank tumors in almost a third of patients in a Phase 2 clinical trial, was featured at the recent 16th Annual Needham Healthcare Conference ... Read more

April 7, 2017April 7, 2017

HEG1 Protein is a Specific, Sensitive Biomarker for Malignant Mesothelioma, Japanese Study Finds

News

Japanese researchers have demonstrated that the modified form of the HEG1 protein is a highly specific marker and a useful diagnostic tool for malignant mesothelioma (MM). The protein is also ... Read more

April 6, 2017April 6, 2017

Novocure’s STELLAR Trial Enrolls Last Mesothelioma Patient to Test Tumor Treating Fields, Chemotherapy Combo

News

Novocure has enrolled its last patient in the STELLAR trial (NCT02397928) to assess the safety and effectiveness of Tumor Treating Fields (TTFields) in combination with standard chemotherapy in newly diagnosed, ... Read more

April 5, 2017April 5, 2017

MPM Tumors Are Genetically Heterogeneous, Triggering Unique Responses from Immune System

News

Each malignant pleural mesothelioma (MPM) tumor site harbors different genetic mutations, and each one triggers a specific immune system’s response, according to a recent study by the University of Chicago’s ... Read more

April 4, 2017

First Patient Dosed in Phase 1 Study of Genolimzumab for Mesothelioma, Other Solid Tumors

News

CBT Pharmaceuticals has enrolled the first participant in a Phase 1 trial assessing genolimzumab (CBT-501) as a treatment for recurrent or refractory solid tumors. The study is expected to include 50 ... Read more

April 3, 2017

ADAO Applauds US Senate for Declaring April 1-7 National Asbestos Awareness Week

News

The Asbestos Disease Awareness Organization (ADAO) is praising the U.S. Senate for unanimously passing its 13th annual resolution establishing April 1-7 as National Asbestos Awareness Week (Senate Res. 98), seeking to raise ... Read more

March 31, 2017

Crizotinib-Afatinib Combination Halves Mesothelioma Growth in Mice, Study Shows

News

A combination of crizotinib and afatinib does a better job of inhibiting the growth of malignant pleural mesothelioma (MPM) cancer cells than either therapy alone, according to a study. Together, ... Read more

March 30, 2017

Mesothelioma Patients Who Receive IMPRINT Radiotherapy Live Longer, Study Shows

News

Mesothelioma patients treated with chemotherapy and a modern type of radiotherapy called IMPRINT survive longer after lung-sparing surgery than patients who received conventional radiotherapy, an analysis of patient outcomes indicates. ... Read more